NRx Pharmaceuticals’ (NRXP) Buy Rating Reiterated at D. Boral Capital

D. Boral Capital reissued their buy rating on shares of NRx Pharmaceuticals (NASDAQ:NRXP) in a research note issued to investors on Monday,Benzinga reports. D. Boral Capital currently has a $31.00 target price on the stock.

NRXP has been the subject of several other research reports. Ascendiant Capital Markets raised their target price on NRx Pharmaceuticals from $44.00 to $45.00 and gave the company a “buy” rating in a research note on Monday, December 2nd. HC Wainwright restated a “buy” rating and set a $19.00 price objective on shares of NRx Pharmaceuticals in a research report on Thursday, March 20th.

NRx Pharmaceuticals Trading Up 3.0 %

Shares of NASDAQ:NRXP opened at $2.07 on Monday. The company has a 50 day moving average of $2.66 and a 200-day moving average of $2.04. The firm has a market cap of $35.02 million, a P/E ratio of -0.97 and a beta of 1.22. NRx Pharmaceuticals has a twelve month low of $1.10 and a twelve month high of $6.01.

NRx Pharmaceuticals (NASDAQ:NRXP) last released its earnings results on Friday, March 14th. The company reported ($0.30) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.10). Equities research analysts forecast that NRx Pharmaceuticals will post -1.75 EPS for the current year.

Institutional Investors Weigh In On NRx Pharmaceuticals

A number of institutional investors and hedge funds have recently modified their holdings of NRXP. Townsquare Capital LLC acquired a new position in shares of NRx Pharmaceuticals in the 3rd quarter valued at $25,000. Sassicaia Capital Advisers LLC acquired a new stake in NRx Pharmaceuticals during the 4th quarter worth about $33,000. Squarepoint Ops LLC acquired a new position in shares of NRx Pharmaceuticals in the fourth quarter worth about $56,000. Millennium Management LLC purchased a new position in shares of NRx Pharmaceuticals in the fourth quarter worth approximately $61,000. Finally, Anson Funds Management LP acquired a new stake in shares of NRx Pharmaceuticals during the third quarter valued at approximately $241,000. 4.27% of the stock is owned by institutional investors and hedge funds.

NRx Pharmaceuticals Company Profile

NRx Pharmaceuticals, Inc, a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned food and drug administration-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior.